The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical naloxegol product for opioid-induced constipation failed one of its Phase III trials rather than passed it, as the companies indicate. Feuerstein's skepticism is based on AZN retrieving data from one patient that was thought to be non-retrievable after the database for the trial had been locked.